trametinib
NICE Recommends Novartis' BRAF, MEK Inhibitor Combo for BRAF-Mutant Pediatric Glioma
The UK's National Institute for Health and Care Excellence recommended the combination treatment for pediatric patients with BRAF V600E-mutant low- or high-grade glioma.
Researchers hope their study will show that tests for gene variants and DNA methylation can predict which lower-risk patients may be cured without a stem cell transplant.
Erasca, Novartis Ink Deal to Study Mekinist, Naporafenib Combo in RAS/MAPK-Driven Cancers
Novartis will provide Mekinist for Erasca's SEACRAFT-1 and SEACRAFT-2 trials in RAS Q61X-mutant solid tumors and NRAS-mutant melanoma, respectively.
Novartis Focused on Radiopharmaceutical Expansion After Pluvicto, Lutathera Sales Both Grow in Q3
Premium
The Swiss drugmaker also reported revenue increases across other precision oncology products including its breast cancer drug Kisqali.
NICE Recommends Novartis' Tafinlar-Mekinist as Frontline Treatment for BRAF-Mutant NSCLC
The agency estimated that the drug combination's cost-effectiveness falls within what it considers an acceptable use of the NHS's resources.